In multiple myeloma, circ-CCT3 binds miR-223-3p, attenuating the miR-223-3p-mediated repression of bromodomain containing 4 (BRD4) to sensitize cells to bortezomib treatment [18]. This evidence concerns the gene BRD4 and plasma cell myeloma.